Nymox Pharmaceutical Management
Management criteria checks 4/4
Nymox Pharmaceutical's CEO is Paul Averback, appointed in Sep 1995, has a tenure of 28.67 years. directly owns 35.89% of the company’s shares, worth $11.72M. The average tenure of the management team and the board of directors is 5.8 years and 13.4 years respectively.
Key information
Paul Averback
Chief executive officer
US$746.7k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 28.7yrs |
| CEO ownership | 35.9% |
| Management average tenure | 5.8yrs |
| Board average tenure | 13.4yrs |
Recent management updates
Recent updates
Nymox gets FDA feedback on NDA resubmission for lead asset
Sep 13Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Aug 17
NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq
Jul 14Nymox to file for Fexapotide approval by mid-September
May 06Nymox under pressure on $8M private placement
Apr 28What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition
Mar 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$5m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$3m |
| Dec 31 2022 | US$747k | n/a | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | n/a | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | n/a | n/a | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$13m |
| Dec 31 2019 | US$2m | n/a | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$13m |
| Jun 30 2019 | n/a | n/a | -US$14m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$2m | US$600k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$5m | US$5m | -US$13m |
Compensation vs Market: Paul's total compensation ($USD746.75K) is about average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Averback (72 yo)
28.7yrs
Tenure
US$746,749
Compensation
Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.7yrs | US$746.75k | 35.89% $ 11.7m | |
| QA and Compliance Manager | 5.8yrs | no data | no data | |
| VP, General Counsel & Director | less than a year | no data | no data |
5.8yrs
Average Tenure
Experienced Management: NYMX.F's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.7yrs | US$746.75k | 35.89% $ 11.7m | |
| VP, General Counsel & Director | less than a year | no data | no data | |
| Independent Director | 17.9yrs | US$3.97k | 0.00042% $ 137.2 | |
| Independent Director | 8.8yrs | US$3.97k | 5.12% $ 1.7m |
13.4yrs
Average Tenure
72yo
Average Age
Experienced Board: NYMX.F's board of directors are seasoned and experienced ( 13.4 years average tenure).